AdisInsight Review H1 2022 Report

It's free to preview the report, or fill out the quick form for full access

This new report summarizes the development of drugs in the first half of 2022, highlighting significant trends in drug research, clinical trials, and commercial deals in R&D and drug safety information as seen through the AdisInsight database.

Preview the report for free now

Drawing from data and intelligence found in our database, our report aims to present an updated overview of drug development over the first half of 2022, including: 

  • Research trends 
  • Trial activity and success rates
  • The most often reported adverse events
  • Key deals

To access the full report, please submit this form:

Fill in all fields correctly.A technical error occurred.

*We collect and use your personal data to facilitate your request. We won’t contact you for anything unrelated to this request, neither will we share your information with any third parties, as detailed in our privacy policy. We may share it with our affiliated companies and use it internally for analysis purposes.

Here is what comes ONLY in the full report

  • Drugs to watch 
  • New drug profiles added in H1 2022
  • Top 10 AdisInsight drug profiles viewed